[1]中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015版)[J].临床与实验病理学杂志,2015,(03):241-246.
点击复制

原发性肝癌规范化病理诊断指南(2015版)

参考文献/References:

[1] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌学组,等. 原发性肝癌规范化病理诊断方案专家共识[J]. 临床与实验病理学杂志, 2010, 26(6):645-7.
[2] Koh C, Zhao X, Samala N, et al. AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations[J]. Hepatology, 2013,58(6):2142-52.
[3] William H, Ralph H, Timothy H, et al. Surgical pathology dissection: an illustrated guide[M]. New York:Springer, 2003:7-9.
[4] 中华医学会编著. 临床技术操作规范·病理学分册[M]. 北京:人民军医出版社, 2004:27-41.
[5] Bass B P, Engel K B, Greytak S R, et al. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded(FFPE)tissue: how well do you know your FFPE specimen[J]? Arch Pathol Lab Med, 2014,138(11):1520-30.
[6] Lu X Y, Xi T, Lau W Y, et al. Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior[J]. Ann Surg Oncol, 2011,18(8):2210-7.
[7] Cai S W, Yang S Z, Gao J, et al. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma[J]. Surgery, 2011,149(4):576-84.
[8] 应越英. 肝细胞肝癌的病理学[M]//汤钊猷.原发性肝癌. 上海:科学技术出版社, 1981:115-46.
[9] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011版)[J]. 临床肝胆病杂志, 2011,27(11):1141-59.
[10] Nakanuma Y, Curado M P, Franceschi S, et al. Intrahepatic cholangiocarcinoma[M]//Bosman F T, Carneiro F, Hruban R H, et al. WHO classification of tumours of the digestive system. 4 th ed. Lyon:IARC Press, 2010:217-27.
[11] Cong W M, Wu M C. Small hepatocellular carcinoma: current and future approaches[J]. Hepatol Int, 2013,7(3):805-12.
[12] Lu X Y, Xi T, Lau W Y, et al. Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior[J]. J Cancer Res Clin Oncol, 2011, 137(4):567-75.
[13] Moribe T, Iizuka N, Miura T, et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma[J]. Int J Cancer, 2009, 125(2):388-97.
[14] Llovet J M, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis[J]. Gastroenterology, 2006, 131(6):1758-67.
[15] Ueno S, Kubo F, Sakoda M, et al. Efficacy of anatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification[J]. J Hepatobiliary Pancreat Surg, 2008,15(5):493-500.
[16] Farinati F, Sergio A, Baldan A, et al. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study[J]. BMC Cancer, 2009,9:33.
[17] 吴孟超. 应重视小肝癌的诊断与治疗[J]. 中华医学杂志, 2007,87(30):2089-91.
[18] Theise N D, Curado M P, Franceschi S, et al. Hepatocellular carcinoma[M]// Bosman F T, Carneiro F, Hruban R H, et al. WHO classification of tumours of the digestive system. 4th ed. Lyon:IARC Press, 2010:205-16.
[19] 胡锡琪. 慢性肝炎肝纤维化病理分期和评估[J]. 中华肝脏病杂志, 2008,16(3):169-70.
[20] Desmet V J, Gerber M, Hoofnagle J H, et al. Classification of chronic hepatitis: diagnosis, grading and staging[J]. Hepatology, 1994,19(6):1513-20.
[21] Knodell R G, Ishak K G, Black W C, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J]. Hepatology, 1981,1(5):431-5.
[22] Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment[J]. J Hepatol, 1991,13(3):372-4.
[23] Batts K P, Ludwig J. Chronic hepatitis. An update on terminology and reporting[J]. Am J Surg Pathol, 1995,19(12):1409-17.
[24] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group[J]. Hepatology, 1996,24(2):289-93.
[25] Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis[J]. J Hepatol, 1995,22(6):696-9.
[26] 中华医学会传染病与寄生虫病学分会, 肝病学分会. 病毒性肝炎防治方案[J]. 中华肝脏病杂志, 2000,8(6):324-9.
[27] International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia[J]. Hepatology, 2009,49(2):658-64.
[28] Di Tommaso L, Sangiovanni A, Borzio M, et al. Advanced precancerous lesions in the liver[J]. Best Pract Res Clin Gastroenterol, 2013,27(2):269-84.
[29] Toyosaka A, Okamoto E, Mitsunobu M, et al. Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma, the role of efferent vessels[J]. HPB Surg, 1996,10(2):97-103.
[30] Toyosaka A, Okamoto E, Mitsunobu M, et al. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel[J]. Am J Gastroenterol, 1996,91(8):1610-5.
[31] Rodriguez-Peralvarez M, Luong T V, Andreana L, et al. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability[J]. Ann Surg Oncol, 2013,20(1):325-39.
[32] Eguchi S, Takatsuki M, Hidaka M, et al. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection[J]. World J Surg, 2010,34(5):1034-8.
[33] Iguchi T, Shirabe K, Aishima S, et al. New pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantation[J].Transplantation, 2014. [Epub ahead of print].
[34] Du M, Chen L, Zhao J, et al. Microvascular invasion(MVI)is a poorer prognostic predictor for small hepatocellular carcinoma[J]. BMC Cancer, 2014,14:38.
[35] Roayaie S, Blume I N, Thung S N, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma[J]. Gastroenterology, 2009,137(3):850-5.
[36] Sumie S, Nakashima O, Okuda K, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma[J]. Ann Surg Oncol, 2014,21(3):1002-9.
[37] Pawlik T M, Delman K A, Vauthey J N, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma[J]. Liver Transpl, 2005,11(9):1086-92.
[38] Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features[J]. Cancer, 2002,95(9):1931-7.
[39] Lim C, Mise Y, Sakamoto Y, et al. Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma[J]. World J Surg, 2014,38(11):2910-8.
[40] 石 明,张昌卿,冯凯涛,等. 肝细胞癌周围微小转移分布的研究[J]. 中华肿瘤杂志, 2002,4(3):257-60.
[41] Chiche L, Menahem B, Bazille C, et al. Recurrence of hepatocellular carcinoma in noncirrhotic liver after hepatectomy[J]. World J Surg, 2013,37(10):2410-8.
[42] Meniconi R L, Komatsu S, Perdigao F, et al. Recurrent hepatocellular carcinoma: a western strategy that emphasizes the impact of pathologic profile of the first resection[J]. Surgery, 2015,157(3):454-62.
[43] Rockey D C, Caldwell S H, Goodman Z D, et al. Liver biopsy[J]. Hepatology, 2009,49(3):1017-44.
[44] 丛文铭,董 辉,冼志红. 肝脏和肝内胆管系统肿瘤[M]//吴秉铨,刘彦仿. 免疫组织化学病理诊断. 2版. 北京:北京科学技术出版社, 2013:334-45.
[45] Ordonez N G. Arginase-1 is a novel immunohistochemical marker of hepatocellular differentiation[J]. Adv Anat Pathol, 2014,21(4):285-90.
[46] Govaere O, Komuta M, Berkers J, et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas[J]. Gut, 2014,63(4):674-85.
[47] Xia L, Huang W, Tian D, et al. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma[J]. J Hepatol, 2012,57(3):600-12.
[48] Roessler S, Budhu A, Wang X W. Deciphering cancer heterogeneity: the biological space[J]. Front Cell Dev Biol, 2014,2:12.
[49] Yang X, Zhang X F, Lu X, et al. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway[J]. Hepatology, 2014,59(5):1874-85.
[50] Wang B, Xia C Y, Lau W Y, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery[J]. J Am Coll Surg, 2013,217(6):1054-62.
[51] 朱玉瑶,顾怡瑾,陆新元,等. 二例术后远期复发性肝细胞癌的克隆特点分析[J]. 中华肿瘤杂志, 2014,36(6):450-2.
[52] Matsumoto Y, Fujii H, Matsuda M, et al. Multicentric occurrence of hepatocellular carcinoma: diagnosis and clinical significance[J]. J Hepatobiliary Pancreat Surg, 2001,8(5):435-40.
[53] Finkelstein S D, Marsh W, Demetris A J, et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma[J]. Hepatology, 2003,37(4):871-9.
[54] Gehrau R, Mas V, Archer K J, et al. Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation[J]. Expert Rev Gastroenterol Hepatol, 2011,5(4):539-52.
[55] 丛文铭,吴孟超. 肝癌分子病理诊断新思路与临床治疗新策略[J]. 中华医学杂志, 2014, 94(20):1521-3.

相似文献/References:

[1]中国抗癌协会肝癌专业委员会、中国抗癌协会临床肿瘤学协作专业委员会、 中华医学会肝病学会肝癌学组、全国肝胆肿瘤及移植病理协作组.原发性肝癌规范化病理诊断方案专家共识[J].临床与实验病理学杂志,2010,(06):645.
[2]江慧,刘晓红,曹志新,等.肝细胞癌中Wnt5a、Ror2蛋白的表达及临床意义[J].临床与实验病理学杂志,2010,(06):652.
 JIANG Hui,LIU Xiao hong,CAO Zhi xin,et al.Expression of Wnt5a and Ror2 in hepatocellular carcinoma and their clinical significance[J].Chinese Journal of Clinical and Experimental Patholog,2010,(03):652.
[3]曾思恩,肖胜军,张小玲,等.肝细胞肝癌中转录辅抑制因子CtBP1与其靶基因Ecadherin的表达[J].临床与实验病理学杂志,2010,(06):655.
 ZENG Si en,XIAO Sheng jun,ZHANG Xiao ling,et al.Expression of transcriptional corepressors CtBP1 and its target gene Ecadherin in hepatocellular carcinoma[J].Chinese Journal of Clinical and Experimental Patholog,2010,(03):655.
[4]刘静,郭文君,韩献成,等.内皮抑素对HepG2细胞生长的影响及机制研究[J].临床与实验病理学杂志,2008,(06):709.
 LIU Jing,GUO Wen jun,HAN Xian cheng,et al.Effect of endostatin on proliferation and its mechanisms[J].Chinese Journal of Clinical and Experimental Patholog,2008,(03):709.
[5]陈定宝,宋秋静,沈丹华.肝树突细胞肿瘤2例报道并文献复习[J].临床与实验病理学杂志,2012,(12):1386.
[6]李晓杰,胡玉林,谢志斌,等.肝细胞癌中EMS1蛋白的表达[J].临床与实验病理学杂志,2008,(02):17.
 LI Xiao jie,HU Yu lin,XIE Zhi bing,et al.Expression of EMS1 protein in hepatocelluar carcinoma[J].Chinese Journal of Clinical and Experimental Patholog,2008,(03):17.
[7]刘瑶,廖跃光,黄才斌,等.肝细胞癌组织中PEG10、SIAH2的表达及其意义[J].临床与实验病理学杂志,2012,(04):371.
 LIU Yao,LIAO Yue guang,HUANG Cai bin,et al.Expression of PEG10 and SIAH2 in hepatocellular carcinoma and their clinical implications[J].Chinese Journal of Clinical and Experimental Patholog,2012,(03):371.
[8]蒋艳霞,李宏,李玉军.原发性肝细胞癌组织中Connexin43和CD147的表达及意义[J].临床与实验病理学杂志,2012,(04):374.
 JIANG Yan xia,LI Hong,LI Yu jun.Expression of Cx43 and CD147 and their significance in primary hepatocellular carcinoma[J].Chinese Journal of Clinical and Experimental Patholog,2012,(03):374.
[9]胡少为,杨海峰,王智园,等.肝细胞癌中ZHX2、NFYA及AFP表达的相关关系[J].临床与实验病理学杂志,2011,(10):1039.
 HU Shao wei,YANG Hai feng,WANG Zhi yuan,et al.Relations between ZHX2, NFYA and AFP expression in HCC tissues[J].Chinese Journal of Clinical and Experimental Patholog,2011,(03):1039.
[10]褚晓磊,吴永平,柳红,等.肝细胞性肝癌中Hep27和MDM2蛋白的表达及意义[J].临床与实验病理学杂志,2011,(09):1002.
[11]周正平,纪小龙.肝细胞癌介入治疗后切除病肝标本4例病理学观察[J].临床与实验病理学杂志,2012,(10):1167.
[12]王 博,姚冬颖,许 欣,等.肝脏原发性神经内分泌瘤2例[J].临床与实验病理学杂志,2019,(04):503.

更新日期/Last Update: 2015-03-30
版权所有© 2010  临床与实验病理学杂志
地址:合肥市梅山路81号安徽医科大学内     电话:0551-65161102
皖ICP备11021972号-2